BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/27/2025 7:54:00 AM | Browse: 93 | Download: 287
 |
Received |
|
2025-07-31 02:20 |
|
Peer-Review Started |
|
2025-07-31 02:20 |
|
First Decision by Editorial Office Director |
|
2025-08-19 09:15 |
|
Return for Revision |
|
2025-08-19 09:15 |
|
Revised |
|
2025-08-26 01:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-06 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-06 08:14 |
|
Articles in Press |
|
2025-11-06 08:14 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-17 01:04 |
|
Publish the Manuscript Online |
|
2025-11-27 07:54 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tulio L Correa and Nikki Duong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tulio L Correa, MD, Post Doctoral Researcher, Division of General Internal Medicine, University of Pittsburgh Medical Center, No. 200 Lothrop Street, Pittsburgh, PA 15222, United States. correatl@upmc.edu |
| Key Words |
Non-alcoholic fatty liver disease; Fatty liver; Diabetes mellitus; Metabolic dysfunction-associated steatotic liver disease; Type 2 diabetes mellitus |
| Core Tip |
The transition from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease refocuses diagnosis on metabolic dysfunction, capturing a broader spectrum of patients with type 2 diabetes mellitus and hepatic steatosis. Metabolic dysfunction-associated steatotic liver disease and its related category, metabolic and alcohol-associated liver disease, improve disease recognition, prevalence estimation, and management strategies compared to non-alcoholic fatty liver disease. This minireview highlights the clinical implications of these changes, including the need for reclassification in trials, metabolic-targeted treatments, and multidisciplinary approaches to enhance screening and outcomes in type 2 diabetes mellitus populations. |
| Publish Date |
2025-11-27 07:54 |
| Citation |
Correa TL, Duong N. Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes. World J Hepatol 2025; 17(11): 112573 |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i11/112573.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i11.112573 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
